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Introduction
18 F-fluoro-deoxy-glucose (FDG), an 18 F-labeled glucose analog, is the most common radiotracer for positron emission tomography (PET) in cancer diagnosis [1] . However, FDG-PET has several limitations in practice, for example, FDG cannot distinguish tumor tissues from inflammatory or normal brain tissues. Therefore, 18 F-labeled amino acidbased radiotracers have been reported as an alternative, which is based on the fact that tumor cells take up and consume more amino acids to maintain their sustained fast growth. Among those radiotracers, 18 F-labeled alpha-methyl tyrosine (AMT) has shown high tumor uptake and great ability to differentiate tumor tissue from inflammatory sites in brain tumors and squamous cell carcinoma [2] . 18 F-AMT enters the tumor cells via L-type amino acid transporters (LAT), which is the only system that can transport large neutral amino acids with aromatic rings [3] . LAT, especially its subtype LAT1, was reported to be highly expressed in many cancer cell lines and positively correlates with tumor growth [4, 5] . So far, 18 F-AMT is the most suitable amino acid transporter-targeting radiotracer for tumor imaging, regardless of low synthesis yield and requirement of an onsite cyclotron to produce 18 F.
Although PET has emerged as an advanced imaging tool for cancer diagnosis, only limited facilities around the world can afford complete armamentarium of PET and cyclotron for the local production of short-lived positron-emitting radionuclides such as 11 C and 18 F. Therefore, mature technologies, that is, single photon emission computed tomography (SPECT) or its combination with computed tomography (CT), still play important and irreplaceable roles in nuclear imaging area [6] . The most common radionuclide for SPECT is technetium-99m ( 99m Tc, t 1/2 = 6.02 h), which is produced by in-house generator and does not require the cyclotron [7] . Due to their similar chemistry, the diagnostic radioisotope 99m Tc and the therapeutic radioisotope rhenium-188 ( 188 Re) could be labeled to the same ligand, which leads to the diagnostic/therapeutic matched pair. Unlike most of the cyclotron-produced radionuclides that utilize the covalent chemistry for labeling, 99m Tc requires a "chelator" to conjugate the radionuclide with the target ligand. The nitrogen, oxygen, and sulfur combinations have been shown to be stable chelators for 99m Tc such as N 4 (e.g., DOTA, cyclam-14), N 3 S (e.g., MAG-3), N 2 S 2 (e.g., ECD), NS 3 , S 4 (e.g., sulfur colloid), diethylenetriamine pentaacetic acid (DTPA), O 2 S 2 (e.g., DMSA), and hydrazinonicotinamide (HYNIC) [8] [9] [10] [11] [12] [13] .
Here, we report the synthesis of precursor O-[3-(1,4,8,11-tetraazacyclotetradecan)-propyl]-α-methyl tyrosine (N 4 -AMT) and its radiolabeling with 99m Tc. In vitro cellular uptake kinetics and planar scintigraphic imaging of 99m Tc-N4-AMT were also evaluated.
Materials and Methods
All chemicals of analytical grade and solvents of HPLC grade for compound synthesis were purchased from Sigma-Aldrich (St. Louis, MO). 1 H-, 13 C-NMR spectra were performed on Bruker 300 MHz spectrometer in CDCl 3 , CD 3 OD, and D 2 O. Tetramethylsilane was used as an external standard. Chemical shifts were reported in δ (ppm) and J values in hertz. Sodium pertechnetate (Na 99m TcO 4 ) was obtained from 99 Mo/ 99m Tc generator in Mallinckrodt (Houston, TX).
Synthesis of Precursor N4-AMT

α-Methyl Tyrosine Ethylester 2.
The synthetic strategies for precursor N 4 -AMT are demonstrated in Figure 1 . Thionyl chloride (10 mL; 137.42 mmol) was added to a solution of α-methyltyrosine 1 (10.00 g; 51.22 mmol) in anhydrous ethanol (60 mL) at 0
• C, and then heated at 78
• C for 4 h while stirring. After cooling, the reaction mixture was reduced to 20 mL, and then 10 mL of triethylamine was added into it. The mixture was poured into 100 mL of water and extracted with chloroform. The combined organic layers were dried over MgSO 4 
N-t-Butoxycarbonyl-O-[3-Br-Propyl]-α-Methyl Tyrosine Ethylester 5.
A solution of 4 (5.44 g; 16.82 mmol) and 1,3-dibromopropane (136.74 g; 677.30 mmol) in 100 mL acetone was purged with nitrogen for 15 min. Potassium carbonate (22.62 g; 163.69 mmol) was added to the reaction mixture, the mixture was then refluxed for 12 h at 75
• C. After the removal of solvents and excessive reagents under reduced pressure, the residue was dissolved in chloroform, washed with water, and dried in anhydrous magnesium sulfate. A yellow liquid was purified by silica gel flash chromatography (hexane: ethylacetate, 2 : 1) to furnish compound 5 as pale yellow liquid. Yield: 4.80 g (7.52 mmol, 64.69%). 1 H-NMR (CDCl 3 ) δ = 7.02 (d, 2H, J = 9.00 Hz), 6.82 (d, 2H, J = 9.00 Hz), 4.23 (dd, 2H, J = 27.00), 4.09 (t, 2H, J = 12.00 Hz), 3 
N-t-Butoxycarbonyl-O-[3-(N
Compound 6 (1.00 g; 3.93 mmol) was dissolved in 20 mL of anhydrous DMF and treated with a solution of Nt-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine ethylester 5 (1.74 g; 3.93 mmol) in 40 mL of DMF under nitrogen atmosphere. The reaction mixture was heated to reflux for 18 h at 75
• C and then allowed to cool down to room temperature. The solvent was removed in vacuo. The residue was dissolved in chloroform (30 mL), washed with water and 1 M Na 2 CO 3 , (12 mL), and then separated for the organic layer. It was dried with anhydrous Magnesium sulfate, filtered, and evaporated. The crude compound was purified by silica gel column chromatograph (chloroform: methanol 9 : 1). Yield: 1.00 g (1.63 mmol, 42.00%). 
O-[3-(1,4,8,11-Tetraazabicyclohexadecane)-Propyl]-α-Methyl Tyrosine (N 4 -AMT) 9.
To a solution of compound 8 (0.20 g; 0.39 mmol) in a 5 mL of water, 10 N NaOH (2 mL) was added, stirred, and refluxed over night at 90
• C. The solvent was evaporated under vacuum, giving white solid, which was dissolved in 5 mL of water and neutralized with 5 N HCl solution to pH = 7. It was lyophilized and obtained as white solid. The solid was stirred in 25 mL anhydrous methanol, filtered, and evaporated to afford an off white solid. Yield: 0.20 g (0.46 mmol: 99.0%). 1 H-NMR (D 2 O) δ = 7.21 (d, 2H, J = 9.00 Hz), 7.00 (d, 2H, J = 9.00 Hz), 4.14 (t, 2H, J = 12.0 Hz), 3.10 (m, 5H), 2.94 (m, 2H), 2.84 (m, 13H), 1.95 (m, 6H), 1.33 (s, 3H) ppm. 13 
Radiosynthesis of 99m Tc-N4-AMT.
Radiolabeling of N4-AMT with 99m Tc was performed in a standard manner [14] . Briefly, radiosynthesis of 99m Tc-N4-AMT was achieved by adding a required amount of sodium pertechnetate into a vial containing precursor N4-AMT and SnCl 2 (100 μg). Radiochemical purity was assessed by high-performance liquid chromatography (HPLC), equipped with NaI and UV detector (274 nm), and was performed using a C-18 reverse column with a mobile phase of acetonitrile : water (7 : 3) at a flow rate of 0.5 mL/min. 
In Vitro Cellular Uptake of 99m Tc-N4-AMT.
Rat mammary tumor cell line 13762 was obtained from American Type Culture Collection (Rockville, MD). The same cell line was used to create the animal model for in vivo evaluation. Cells were maintained at 37
• C in a humidified atmosphere containing 5% CO 2 in Dulbecco's modified Eagle's medium and nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY). Cells were plated to 6-well tissue culture plates (2 × 10 5 cells/well) for two days before the study, and incubated with 99m Tc-N4-AMT (0.05 mg/well, 8 uCi/well) or 99m Tc-N4 chelator itself (0.025 mg/well, 8 uCi/well) for 15 min-4 h. After incubation, cells were washed with ice-cold PBS twice and detached by adding 0.5 mL of trypsin. Cells were then collected and the radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN). Data was expressed in mean ± S.D. percent of cellular uptake. Committee (IACUC). Tissue distribution studies of 99m Tc-N4-AMT (study I, n = 9) or 99m Tc-N4 (study II, n = 9) were conducted by using normal female Fischer 344 rats (150 ± 25 g, n = 18) (Harlan Sprague-Dawley, Indianapolis, IN). For each radiotracer, nine rats were divided into three groups for three time intervals (0.5, 2, 4 h). The injection activity was 25 ± 0.5 μCi/rat intravenously. At each time interval, the rats were sacrificed, and the selected tissues were excised, weighed, and measured for radioactivity by gamma counter. Data from each sample were represented as the percentage of the injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted sample of the original injection were used as the reference.
In Vivo Tissue Distribution
Planar Scintigraphic Imaging Studies of 99m Tc-N 4 -AMT.
Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of 13762 rat mammary tumor cell suspension (10 5 cells/rat) into the right posterior legs using 22-gauge needles. Imaging studies were performed 14 to 17 days after inoculation when tumors reached approximately 1 cm in diameter. The anesthetized rats were injected intravenously with 99m Tc-N4-AMT (0.3 mg/rat, 300 μCi/rat; n = 3) or with 99m Tc-N4 (0.15 mg/rat, 300 μCi/rat; n = 3), respectively. Planar scintigraphic images were obtained using M-CAM (Siemens Medical Solutions, Hoffman Estates, IL) equipped with a Low-Energy High-Resolution collimator at 30-120 min. The field of view was 53.3 cm × 38.7 cm. The intrinsic spatial resolution was 3.2 mm and the pixel size was from 19.18 mm (32 × 32, zoom = 1) to 0.187 mm (1024 × 1024, zoom = 3.2). Computer outlined regions of interest (ROI) (counts per pixel) of tumors, and normal muscle tissues at symmetric sites were used to calculate tumor-tomuscle (T/M) ratios.
Results and Discussion
3.1. Chemistry. N4-AMT was synthesized via an eightstep procedure (Figure 1 ). Commercially available α-methyl tyrosine 1 was converted into corresponding acid chloride, then to ethyl ester by reacting with thionyl chloride in ethanol. The amine in α-methyl tyrosine ethyl ester 2 was protected as its Boc-derivative Nt-butoxycarbonyl-α-methyl tyrosine ethylester 3 with triethylamine and di-t-butyldicarbonate in DMF. The chain at the -OH group was extended when compound • C promoted the hydrolysis of ester to acid and a simultaneous deoxalation of 7 to yield the final compound O- [3-(1,4,8,11-tetraazacyclotetradecan) -propyl]-α-methyl tyrosine (N 4 -AMT) 8. The total synthesis yield was 14%, which can be adapted to industrial manufacturing. The structure and purity of the compounds at each step were validated by 1 H-and 13 C-NMR, mass spectra, and HPLC. Figure 2 , precursor N4-AMT could be labeled with 99m Tc successfully in a high radiochemical purity (>96%). The retention time of 99m Tc-N4-AMT was 6.899 min. Given that 99m Tc-N4-AMT is a kit-product and labeled without any further purification, the radiochemical yield was assumed to be identical to its radiochemical purity. In this study, we labeled amino acid α-methyltyrosine AMT with 99m Tc using cyclam N4 as the chelator because of its stable chelating ability and fast renal clearance. 99m Tc was selected as the radionuclide due to its favorable physical characteristics, suitable half-life, and costeffectiveness.
Radiosynthesis. As shown in
In Vitro Cellular Uptake of 99m
Tc-N4-AMT. The cellular uptake kinetics of 99m Tc-N4-AMT and 99m Tc-N4 in rat breast tumor cell line 13762 is shown in Figure 3 . There was a drastically increased uptake for 99m Tc-N4-AMT in the tumor cells at 15-240 min, but not for 99m Tc-N4 chelator. These findings suggest that by adding the amino acid AMT, 99m Tc-N 4 -AMT can enter and accumulate into tumor cells effectively and rapidly. To further investigate the transport mechanisms of 99m Tc-N 4 -AMT, the competitive inhibition study using various types of transporter inhibitors will be conducted in the future.
In Vivo Evaluation of 99m
Tc-N 4 -AMT. The result of the in vivo biodistribution studies in the normal Fischer rats at 0.5, 2, and 4 hours after intravenous administration of 99m Tc-N4-AMT is shown in Table 1 . Planar scintigraphic images of 99m Tc-N4-AMT and 99m Tc-N4 at 30, 60, and 120 min in breast tumor-bearing rats are shown in Figure 4 . T/M ratios of 99m Tc-N4-AMT were 2.3-4.0, whereas those of 99m Tc-N4 were 1.9-2.5, respectively. Tumors could be clearly visualized by 99m Tc-N4-AMT, but not by 99m Tc-N4. In addition, the rat kidneys showed intense activity of 99m Tc-N4-AMT in the planar images, which was consistent with the results from the in vivo biodistribution studies in the normal rats. This may be due to the nature of AMT, an inhibitor of tyrosine hydroxylase that cannot be excreted from kidneys and hence crystallized in the proximal tubules because of its poor solubility at the hydrogen ion concentrations of body fluids (pH 5-8) [15] . In the future, in vivo uptake blocking study using the unlabeled AMT will be performed to ascertain whether accumulation of 99m Tc-N4-AMT in the kidney is attributed to AMT module.
Conclusion
In conclusion, efficient synthesis of N4-AMT was achieved. In vitro cellular uptake and in vivo imaging findings collectively suggest that 99m Tc-N4-AMT is a potential radiotracer for breast cancer imaging. In compliance with the chelating capability of N4, N4-AMT could be labeled with positron emitting radionuclides such as Gallium-68 or with shortranged beta emitters for internal radiotherapeutic purposes hereafter.
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